Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Crispr therapeutics ag save search
Europe Gene Editing Technologies Market Report 2024: Analysis and Forecasts 2023-2032 - Leveraging Collaboration as a Major Key Strategies to Create Opportunities
Published: 2024-02-07 (Crawled : 04:00) - prnewswire.com
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 0.18%
H: 0.31%
C: -1.91%
CLLS | $2.47 0.4% 12K
|
Health Technology
|
| O: -0.67%
H: 1.01%
C: 1.01%
europe report collaboration key market
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 0.01%
H: 0.1%
C: -1.09%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 1.22%
H: 8.3%
C: -9.19%
fda crispr disease approval cell treatment therapeutics
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
Published: 2023-02-27 (Crawled : 16:00) - biospace.com/
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 2.44%
H: 0.67%
C: -0.06%
care conference crispr health therapeutics
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Published: 2022-11-01 (Crawled : 22:00) - biospace.com/
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 2.81%
H: 0.63%
C: -3.33%
crispr therapeutics financial update results
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
Published: 2022-10-27 (Crawled : 13:00) - biospace.com/
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 0.74%
H: 0.13%
C: -5.84%
crispr therapeutics
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
Published: 2022-09-27 (Crawled : 12:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: 1.14%
H: 3.43%
C: 1.72%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 3.01%
H: 5.75%
C: 1.1%
global crispr disease therapeutics
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
Published: 2022-06-02 (Crawled : 16:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -0.31%
H: 0.89%
C: 0.55%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: -0.59%
H: 8.12%
C: 6.03%
ctx001 crispr therapeutics
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 1.9%
H: 4.42%
C: 2.94%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 2.37%
H: 2.27%
C: 1.62%
financial results therapeutics crispr report results
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes-Initiation of patient enrollment expected by year-end-
Published: 2021-11-16 (Crawled : 14:00) - biospace.com/
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: -5.24%
H: 0.0%
C: 0.0%
crispr diabetes treatment therapy trial enroll
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -10.49%
H: 3.1%
C: -0.53%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 4.42%
H: 0.63%
C: -1.69%
crispr treatment europe therapy ctx001
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 15:15) - globenewswire.com
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -0.44%
H: 1.7%
C: 0.29%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: -2.06%
H: 2.89%
C: -0.56%
crispr europe therapy ctx001
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia
Published: 2021-04-26 (Crawled : 13:15) - biospace.com/
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
|
| O: -0.07%
H: 0.25%
C: -0.35%
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: 1.32%
H: 7.31%
C: 5.85%
crispr europe ctx001 primec designation
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.